Center for Reproductive Health and Gynecology in Beverly Hills CA, and Yikon Genomics, Have Launched Non-Invasive PGT-A
Yikon Genomics has entered into a strategic cooperation with CRHG to officially launch Yikon's NICS assay for commercial clinical services.
10 Apr, 2019, 11:00 ET
BEVERLY HILLS, Calif., April 10, 2019 /PRNewswire/ -- Center for Reproductive Health & Gynecology (CRHG), a Beverly Hills, California-based IVF center founded by world-renowned reproductive endocrinologist Dr. Sam Najmabadi, has acquired CLIA certification and entered into a strategic cooperation with Yikon Genomics to officially launch Yikon's NICS assay (non-invasive Chromosomal Screening Assay) for commercial clinical services as a comprehensive fertility treatment solution for its patients. Noninvasive PGT-A allows embryos to be screened for chromosomal aneuploidy prior to implantation without the previously utilized invasive methodology of a biopsy. Instead, the culture medium used during in-vitro embryo culture is collected and then processed for aneuploidy screening, through library preparation and NGS (next generation sequencing). This innovative technique enables PGT-A to be performed in an easier, safer, more accurate, and more cost-effective way.
"Being able to provide PGS without the need for an embryo biopsy is a game-changer," expresses Dr. Najmabadi. "It allows us to perform Genetic testing on embryos with no chance of damage to the embryo. It also allows for a more accurate result overall. From my perspective it is a WIN WIN for everyone involved."
"Our goal at Yikon Genomics is to help more families achieve their dreams of conception, through our innovative technologies such as NICS," quotes Brandon Hensinger, Vice President of Sales for Yikon. "The launch of a joint in-house genetic lab at Center for Reproductive Health and Gynecology has enabled Dr. Najmabadi to provide a full suite of services to his patients, and we are honored to be part of the solution that will accomplish the goal of conception for so many people under his care."
Yikon Genomics is a leading solution-based single cell sequencing company based in Shanghai China, with global operations out of the USA, providing complete solutions in the fields of reproductive health and cancer diagnostics. Yikon's ChromInst and NICSInst PGT-A solutions provide the most accurate and comprehensive embryo screening results, to allow physicians to choose healthy embryos for their patients. Yikon's PGT solutions have enabled thousands of couples to achieve healthy pregnancies.
For more information, or for media inquiries, please reach out to Brandon Hensinger at [email protected] or 919-345-1087.
SOURCE Yikon Genomics
Share this article